BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488-496. [PMID: 24856442 DOI: 10.1016/j.clon.2014.04.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Yao JH, Du QY, Zhou YC, Yao TJ, Wu Q, Liu J, Ou YR. Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT. Cancer Manag Res. 2019;11:5133-5146. [PMID: 31213923 DOI: 10.2147/cmar.s203656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
2 Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(29): 6582-6594 [PMID: 27547002 DOI: 10.3748/wjg.v22.i29.6582] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
3 Khawar IA, Park JK, Jung ES, Lee MA, Chang S, Kuh HJ. Three Dimensional Mixed-Cell Spheroids Mimic Stroma-Mediated Chemoresistance and Invasive Migration in hepatocellular carcinoma. Neoplasia. 2018;20:800-812. [PMID: 29981501 DOI: 10.1016/j.neo.2018.05.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
4 Ma JL, Zeng S, Zhang Y, Deng GL, Shen H. Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin. Tumour Biol 2016;37:6177-84. [PMID: 26614432 DOI: 10.1007/s13277-015-4458-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
5 Guo W, Gao J, Zhuang W, Wu Z, Li B, Chen S. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study. JGH Open 2020;4:477-83. [PMID: 32514457 DOI: 10.1002/jgh3.12285] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Wang H, Lv Y, Wang C, Leng D, Yan Y, Blessing Fasae M, Madiha Zahra S, Jiang Y, Wang Z, Yang B, Bai Y. Systematic Analysis of Intestinal MicroRNAs Expression in HCC: Identification of Suitable Reference Genes in Fecal Samples. Front Genet 2019;10:687. [PMID: 31456816 DOI: 10.3389/fgene.2019.00687] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
8 Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019;30:349-357.e2. [PMID: 30819477 DOI: 10.1016/j.jvir.2018.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Liang R, Zhang J, Liu Z, Liu Z, Li Q, Luo X, Li Y, Ye J, Lin Y. Mechanism and Molecular Network of RBM8A-Mediated Regulation of Oxaliplatin Resistance in Hepatocellular Carcinoma. Front Oncol 2020;10:585452. [PMID: 33552961 DOI: 10.3389/fonc.2020.585452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
11 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
12 Liao B, Zhang Y, Sun Q, Jiang P. Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells. Cancer Med 2018;7:196-207. [PMID: 29239146 DOI: 10.1002/cam4.1278] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chou WC, Lee CL, Yang TS, Huang CY, Teng W, Tseng YT, Chen JS, Lin YC, Hou MM, Chang HH, Chia-Hsun Hsieh J. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. J Formos Med Assoc 2018;117:153-63. [PMID: 28392193 DOI: 10.1016/j.jfma.2017.03.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
14 Hong J, Cao L, Xie H, Liu Y, Yu J, Zheng S. Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis. Hepatobiliary Surg Nutr 2021;10:623-30. [PMID: 34760966 DOI: 10.21037/hbsn.2020.03.15] [Reference Citation Analysis]
15 Lei C, Ren D, Fu M, Sun C, Ren H, Pan Q, Li Y. Curative effect of endostar combined with oxaliplatin in the treatment of primary hepatic carcinoma and its influence on immune cells. Oncol Lett 2019;17:3665-70. [PMID: 30881491 DOI: 10.3892/ol.2019.10022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Qin S, Wu Q. Systemic chemotherapy with oxaliplatin is a good option for advanced hepatocellular carcinoma. Hepat Oncol 2015;2:203-7. [PMID: 30190999 DOI: 10.2217/hep.15.14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Hu H, Yang L, Li L, Zeng C. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis. Biochem Biophys Res Commun. 2018;503:2400-2406. [PMID: 29966655 DOI: 10.1016/j.bbrc.2018.06.168] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
18 Oranratnachai S, Rattanasiri S, Pooprasert A, Tansawet A, Reungwetwattana T, Attia J, Thakkinstian A. Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:654020. [PMID: 33869060 DOI: 10.3389/fonc.2021.654020] [Reference Citation Analysis]
19 Shang XY, Yu XQ, Yao GD, Song SJ. Daphnegiravone D from Daphne giraldii induces cell death by targeting ATR in Hep3B cells. Bioorg Chem 2021;110:104802. [PMID: 33730672 DOI: 10.1016/j.bioorg.2021.104802] [Reference Citation Analysis]
20 Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
21 Ray EM, Sanoff HK. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J Hepatocell Carcinoma 2017;4:131-8. [PMID: 29184856 DOI: 10.2147/JHC.S124366] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
22 Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, Ogawa K, Chuma M, Meguro T, Nakamura M, Nagasaka A, Horimoto H, Yamamoto Y, Sakamoto N. A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. Drugs R D 2017;17:381-8. [PMID: 28573606 DOI: 10.1007/s40268-017-0187-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Akkoç Y, Gözüaçık D. Autophagy and liver cancer. Turk J Gastroenterol 2018;29:270-82. [PMID: 29755011 DOI: 10.5152/tjg.2018.150318] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
24 Zheng Z, Liang W, Wang D, Schroder PM, Ju W, Wu L, Zheng Z, Shang Y, Guo Z, He X. Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. Int J Cancer 2015;136:E751-9. [PMID: 25208979 DOI: 10.1002/ijc.29203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ren WW, Li DD, Chen X, Li XL, He YP, Guo LH, Liu LN, Sun LP, Zhang XP. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy. Cell Death Dis 2018;9:547. [PMID: 29749374 DOI: 10.1038/s41419-018-0592-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
26 Liu L, Zheng YH, Han L, Qin SK. Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies. Medicine (Baltimore) 2016;95:e4993. [PMID: 27749557 DOI: 10.1097/MD.0000000000004993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
27 Slotta JE, Kollmar O, Ellenrieder V, Ghadimi BM, Homayounfar K. Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. World J Hepatol 2015; 7(9): 1168-1183 [PMID: 26019733 DOI: 10.4254/wjh.v7.i9.1168] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
28 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 14.4] [Reference Citation Analysis]